ELMD Electromed, Inc.
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1488917 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.1%
TTM net income YoY45.5%
TTM EPS YoY45.7%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR54.4%
Margins
Gross margin79.0%
Operating margin19.5%
Net margin15.8%
FCF margin11.5%
EBITDA margin20.6%
Returns
ROE24.5%
ROA20.8%
ROIC (approx.)34.3%
Asset turnover1.32x
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio7.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio3.6%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $73.78M | $64.00M |
| Cost of revenue | $15.83M | $14.03M |
| Gross profit | $57.94M | $49.97M |
| R&D expense | $1.31M | $996,000 |
| SG&A expense | $42.75M | $39.31M |
| Operating income | $13.88M | $9.66M |
| Pretax income | $14.36M | $10.28M |
| Income tax | $3.06M | $2.75M |
| Net income | $11.30M | $7.54M |
| EBITDA | $14.75M | $10.70M |
| EPS (basic) | 1.37 | 0.89 |
| EPS (diluted) | 1.30 | 0.85 |
| Weighted avg. shares (diluted) | 8.69M | 8.91M |
| Balance sheet | ||
| Cash & equivalents | $20.45M | $15.29M |
| Receivables | $29.80M | $24.66M |
| Inventory | $3.68M | $3.30M |
| Current assets | $57.37M | $45.08M |
| PP&E, net | $5.21M | $4.71M |
| Intangibles | $379,000 | $371,000 |
| Total assets | $66.27M | $53.80M |
| Current liabilities | $12.22M | $10.47M |
| Total liabilities | $12.29M | $10.59M |
| Shareholders' equity | $53.98M | $43.21M |
| Shares outstanding | 8.37M | 8.35M |
| Cash flow statement | ||
| Operating cash flow | $9.66M | $11.39M |
| Capital expenditure | $1.25M | $262,000 |
| Free cash flow | $8.41M | $11.13M |
| Investing cash flow | -$1.30M | -$306,000 |
| Financing cash flow | -$3.20M | -$11.88M |
| Depreciation & amortization | $868,000 | $1.04M |
| Stock-based compensation | $2.72M | $3.06M |
| Share buybacks | $3.92M | $10.00M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.